Rivaroxaban (Xarelto®): Guide de la pratique officinale

Translated title of the contribution: Rivaroxaban: Xarelto® - Recommendations for pharmacists

J Douxfils, S Michel, C Beauloye, M Goethals, P Hainaut, H Heidbuchel, C Hermans, B Ickx, K Jochmans, S Mottes, F Mullier, A Peeters, C Scavée, P Sinnaeve, M Sprynger, V Thijs, C Vandenbroeck, E Vandermeulen, P Verhamme, J M Dogné

Research output: Contribution to journalReview article

828 Downloads (Pure)


Rivaroxaban is one of the new oral anticoagulants (NOACs) (recommended as reference treatments when a long-term anticoagulation is needed). It has many potential advantages in comparison with Vitamin K Antagonists (VKA). It has a predictable anticoagulant effect and does not theoretically require biological monitoring. It is also characterized by less food and drug interactions. However, due to major risks associated with over- and under-dosage, its optimal use in patients should be carefully followed by health care professionals. The aim of this article is to provide recommendations for pharmacists on the practical use of Xarelto® in its different approved indications. This document is adapted from the practical user guide of rivaroxaban which was developed by an independent group of Belgian experts in the field of thrombosis and haemostasis.
Original languageFrench
Pages (from-to)28-36
Number of pages9
JournalJournal de Pharmacie de Belgique
Issue number1
Publication statusPublished - 1 Mar 2013



  • Anticoagulants
  • Humans
  • Morpholines
  • Pharmacists
  • Thiophenes
  • Venous Thrombosis
  • Vitamin K

Cite this

Douxfils, J., Michel, S., Beauloye, C., Goethals, M., Hainaut, P., Heidbuchel, H., Hermans, C., Ickx, B., Jochmans, K., Mottes, S., Mullier, F., Peeters, A., Scavée, C., Sinnaeve, P., Sprynger, M., Thijs, V., Vandenbroeck, C., Vandermeulen, E., Verhamme, P., & Dogné, J. M. (2013). Rivaroxaban (Xarelto®): Guide de la pratique officinale. Journal de Pharmacie de Belgique, (1), 28-36.